ETF Holdings Breakdown of OCUL

OCUL institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	84,893	USD 1,063,709
2025-09-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	35,792	USD 448,474
2025-09-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	98,639	USD 1,235,947
2025-09-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	98,639	USD 1,235,947
2025-09-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,177	USD 14,748 2.3%
Total =		319,140	USD 3,998,825

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with OCUL

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.20 Consensus Target Price from Brokerages

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has been given an average recommendation of “Buy” by the five ratings firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock […] - 2025-09-09 02:46:48

XTX Topco Ltd Increases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

XTX Topco Ltd raised its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 95.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,605 shares of the biopharmaceutical company’s stock after buying an additional 11,012 shares during the quarter. […] - 2025-08-14 04:25:01

Needham & Company LLC Boosts Ocular Therapeutix (NASDAQ:OCUL) Price Target to $15.00

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) had its target price upped by investment analysts at Needham & Company LLC from $14.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential […] - 2025-08-07 04:30:57

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.33 Consensus PT from Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in […] - 2025-08-07 03:12:45

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) gapped down prior to trading on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $12.35, but opened at $11.21. Ocular Therapeutix shares last traded at $11.34, with a volume of 558,460 shares traded. The biopharmaceutical company reported ($0.39) earnings per share […] - 2025-08-07 02:13:01

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Allianz Asset Management GmbH

Allianz Asset Management GmbH lowered its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 41.9% during the first quarter, Holdings Channel.com reports. The fund owned 37,500 shares of the biopharmaceutical company’s stock after selling 27,000 shares during the quarter. Allianz Asset Management GmbH’s holdings in Ocular Therapeutix were worth $275,000 at the end […] - 2025-08-04 05:58:51

Nuveen Asset Management LLC Sells 88,468 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Nuveen Asset Management LLC decreased its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 17.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 414,104 shares of the biopharmaceutical company’s stock after selling 88,468 shares during the period. Nuveen Asset Management LLC’s holdings in Ocular Therapeutix were worth $3,536,000 as […] - 2025-06-02 05:04:52

Millennium Management LLC Acquires New Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Millennium Management LLC acquired a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 447,237 shares of the biopharmaceutical company’s stock, valued at approximately $3,819,000. A number of other hedge […] - 2025-05-30 05:40:53

Bank of America Corp DE Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Bank of America Corp DE lessened its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 43.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 437,071 shares of the biopharmaceutical company’s stock after selling 341,400 shares during the quarter. Bank […] - 2025-05-30 04:54:54

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by ProShare Advisors LLC

ProShare Advisors LLC raised its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 32.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,270 shares of the biopharmaceutical company’s stock after purchasing an additional 12,669 shares during the period. […] - 2025-05-28 08:08:48

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 2,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 3.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 88,463 shares of the biopharmaceutical company’s stock after buying an additional 2,853 shares during the quarter. MIRAE […] - 2025-05-28 05:31:02

D. E. Shaw & Co. Inc. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

D. E. Shaw & Co. Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 31,419 shares of the biopharmaceutical company’s stock, valued at approximately $268,000. A number of other hedge funds and other institutional investors also recently modified their holdings of […] - 2025-05-28 04:42:56

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Deutsche Bank AG

Deutsche Bank AG lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 45.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 456,120 shares of the biopharmaceutical company’s stock after selling 377,454 shares during the period. Deutsche Bank […] - 2025-05-20 05:12:53

Ocular Therapeutix (NASDAQ:OCUL) Shares Down 6.5% After Analyst Downgrade

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report)’s share price fell 6.5% during trading on Tuesday after Needham & Company LLC lowered their price target on the stock from $15.00 to $14.00. Needham & Company LLC currently has a buy rating on the stock. Ocular Therapeutix traded as low as $7.31 and last traded at […] - 2025-05-07 03:05:15

First Trust Advisors LP Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

First Trust Advisors LP bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) during the 4th quarter, Holdings Channel reports. The fund bought 212,944 shares of the biopharmaceutical company’s stock, valued at approximately $1,819,000. A number of other institutional investors and hedge funds have also made changes to their positions […] - 2025-05-06 04:58:55

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Acquired by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 152.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,227 shares of the biopharmaceutical company’s stock after buying an additional 18,251 […] - 2025-05-01 06:12:45

XTX Topco Ltd Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

XTX Topco Ltd bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,593 shares of the biopharmaceutical company’s stock, valued at approximately $99,000. Several other hedge funds have also bought and sold shares of OCUL. […] - 2025-04-30 06:12:51

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Barclays PLC

Barclays PLC decreased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 35.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 331,242 shares of the biopharmaceutical company’s stock after selling 180,280 shares during the period. Barclays PLC’s holdings in Ocular […] - 2025-04-30 05:12:50

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Cut by Legal & General Group Plc

Legal & General Group Plc lowered its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 8.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 104,783 shares of the biopharmaceutical company’s stock after selling 9,296 shares during the quarter. Legal […] - 2025-04-28 04:56:53

Invesco Ltd. Acquires 134,573 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Invesco Ltd. raised its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 17.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 890,046 shares of the biopharmaceutical company’s stock after acquiring an additional 134,573 shares during the period. […] - 2025-04-25 04:58:59

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $16.38 Average PT from Analysts

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price […] - 2025-04-04 02:45:04

Cibc World Markets Corp Invests $124,000 in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Cibc World Markets Corp purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 14,562 shares of the biopharmaceutical company’s stock, valued at approximately $124,000. Several other large investors have also modified their holdings of the stock. AlphaQuest LLC acquired […] - 2025-03-28 06:18:49

Ocular Therapeutix (NASDAQ:OCUL) Coverage Initiated at Royal Bank of Canada

Equities researchers at Royal Bank of Canada started coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) in a report released on Tuesday, Marketbeat reports. The firm set an “outperform” rating and a $17.00 price target on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would indicate a potential upside of […] - 2025-03-20 04:48:56

Needham & Company LLC Begins Coverage on Ocular Therapeutix (NASDAQ:OCUL)

Analysts at Needham & Company LLC initiated coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) in a report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $15.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 77.94% from […] - 2025-03-13 04:22:56

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 […] - 2025-03-07 05:14:55

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) shares gapped down prior to trading on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $7.14, but opened at $6.94. Ocular Therapeutix shares last traded at $6.45, with a volume of 361,162 shares changing hands. The biopharmaceutical company reported […] - 2025-03-05 04:34:51

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 18.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 98,097 shares of the biopharmaceutical company’s stock after purchasing an additional 15,239 shares during the quarter. New York State Common Retirement Fund’s holdings in […] - 2025-03-04 07:17:07

Investors Buy High Volume of Call Options on Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) was the target of unusually large options trading activity on Monday. Stock traders bought 7,643 call options on the stock. This represents an increase of approximately 1,707% compared to the typical volume of 423 call options. Ocular Therapeutix Price Performance Shares of NASDAQ OCUL opened at $5.93 […] - 2025-03-04 06:44:54

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Position Lifted by Rhumbline Advisers

Rhumbline Advisers increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 2.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 213,601 shares of the biopharmaceutical company’s stock after buying an additional 5,682 shares during the period. Rhumbline Advisers’ holdings in Ocular Therapeutix were worth $1,824,000 as of its most recent […] - 2025-03-04 06:12:53

Back to Listing

Disclaimer